دورية أكاديمية

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

التفاصيل البيبلوغرافية
العنوان: Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
المؤلفون: Keefe, S.M., Hoffman-Censits, J., Cohen, R.B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E.G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A.B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N.B. *
المصدر: In Annals of Oncology August 2016 27(8):1579-1585
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1093/annonc/mdw188